share_log

Abbott Laboratories | 10-Q: Q3 2024 Earnings Report

Abbott Laboratories | 10-Q: Q3 2024 Earnings Report

雅培 | 10-Q：2024財年三季報
美股SEC公告 ·  2024/11/01 05:16

Moomoo AI 已提取核心訊息

Abbott Laboratories reported Q3 2024 net sales of $10.6 billion, up 4.9% year-over-year, with organic growth of 7.4% excluding foreign exchange impact. Medical Devices segment led growth with an 11.7% increase to $4.7 billion, driven by strong performance in Diabetes Care where CGM systems sales reached $4.7 billion year-to-date. Operating earnings rose to $1.9 billion from $1.6 billion in Q3 2023.The company's gross profit margin improved to 51.4% from 49.7% in Q3 2023, benefiting from higher pricing and margin improvement initiatives despite foreign exchange headwinds. COVID-19 testing-related sales declined to $265 million from $305 million in the prior year quarter, while core business growth remained strong across segments, particularly in Medical Devices and Established Pharmaceuticals.Looking ahead, Abbott maintains a strong financial position with $7.6 billion in cash and cash equivalents as of September 30, 2024. The company increased its quarterly dividend by 7.8% to $0.55 per share and authorized a new $7 billion share repurchase program in October 2024, demonstrating confidence in its growth trajectory and commitment to shareholder returns.
Abbott Laboratories reported Q3 2024 net sales of $10.6 billion, up 4.9% year-over-year, with organic growth of 7.4% excluding foreign exchange impact. Medical Devices segment led growth with an 11.7% increase to $4.7 billion, driven by strong performance in Diabetes Care where CGM systems sales reached $4.7 billion year-to-date. Operating earnings rose to $1.9 billion from $1.6 billion in Q3 2023.The company's gross profit margin improved to 51.4% from 49.7% in Q3 2023, benefiting from higher pricing and margin improvement initiatives despite foreign exchange headwinds. COVID-19 testing-related sales declined to $265 million from $305 million in the prior year quarter, while core business growth remained strong across segments, particularly in Medical Devices and Established Pharmaceuticals.Looking ahead, Abbott maintains a strong financial position with $7.6 billion in cash and cash equivalents as of September 30, 2024. The company increased its quarterly dividend by 7.8% to $0.55 per share and authorized a new $7 billion share repurchase program in October 2024, demonstrating confidence in its growth trajectory and commitment to shareholder returns.
雅培實驗室報告2024年第三季度淨銷售額達到106億美金，同比增長4.9%，扣除匯率影響後的有機增長爲7.4%。醫療設備部門主導增長，銷售額增長11.7%至47億美金，主要得益於糖尿病護理的強勁表現，CGm系統銷售在本年度已達到47億美金。營業收入從2023年第三季度的16億美金上升至19億美金。公司的毛利潤率從2023年第三季度的49.7%提高到51.4%，儘管受到匯率逆風的影響，仍然受益於價格上漲和利潤改善的舉措。與COVID-19檢測相關的銷售額從去年同期的30500萬美金下降至26500萬美金，而核心業務的增長在各個部門仍然強勁，特別是在醫療設備和成熟製藥領域。展望未來，雅培保持強勁的財務狀況，截至2024年9月30日，現金及現金等價物爲76億美金。公司將季度股息提高7.8%，至每股0.55美金，並於2024年10月授權新的70億美金股票回購計劃，展示了對其增長軌跡的信懇智能和對股東回報的承諾。
雅培實驗室報告2024年第三季度淨銷售額達到106億美金，同比增長4.9%，扣除匯率影響後的有機增長爲7.4%。醫療設備部門主導增長，銷售額增長11.7%至47億美金，主要得益於糖尿病護理的強勁表現，CGm系統銷售在本年度已達到47億美金。營業收入從2023年第三季度的16億美金上升至19億美金。公司的毛利潤率從2023年第三季度的49.7%提高到51.4%，儘管受到匯率逆風的影響，仍然受益於價格上漲和利潤改善的舉措。與COVID-19檢測相關的銷售額從去年同期的30500萬美金下降至26500萬美金，而核心業務的增長在各個部門仍然強勁，特別是在醫療設備和成熟製藥領域。展望未來，雅培保持強勁的財務狀況，截至2024年9月30日，現金及現金等價物爲76億美金。公司將季度股息提高7.8%，至每股0.55美金，並於2024年10月授權新的70億美金股票回購計劃，展示了對其增長軌跡的信懇智能和對股東回報的承諾。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    艾里德克斯
    IRIX
    -- 0.999
    Helius Medical Technologies
    HSDT
    -- 0.4200
    VolitionRX
    VNRX
    -- 0.550
    HeartSciences
    HSCS
    -- 2.9600
    Outset Medical
    OM
    -- 12.580
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    中概股財報季火熱：驚喜盈利能否延續漲勢？
    1. 哪些行業可能成為本輪財報季的市場焦點？ 2. 在政府強調科技創新和可持續發展的背景下，你認為哪些行業具有最大的增長潜力？ 展开
    中國兩會：會議前後股票價格變動的關鍵要點